Navigation Links
Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Date:3/13/2008

sis and resistance of tumors to

chemotherapies.

-- In 2007, Micromet partnered two of its earlier stage programs. The

company is collaborating with Nycomed on the development of MT203, a

human antibody that neutralizes GM-CSF, a key cytokine involved in

autoimmune diseases and chronic inflammation. In addition, Micromet

has licensed MT293 to TRACON Pharmaceuticals, Inc. MT293 is an

anti-angiogenic antibody that aims to limit tumor growth by preventing

blood vessels to reach the tumor. TRACON initiated a phase 1 clinical

trial in July 2007.

-- In June 2007, Micromet closed a $25 million PIPE transaction, adding to

its shareholder base a number of experienced U.S.-based biotech funds.

Several of Micromet's existing shareholders participated in this

financing round.

Summarizing the events, Christian Itin, Ph.D., President and Chief Executive Officer of Micromet said: "In 2007, we have made significant progress with our BiTE antibodies demonstrating strong clinical activity for MT103 in late-stage non-Hodgkin's lymphoma patients and completing preclinical development of MT110, our first BiTE antibody targeting solid tumors. In 2008, we will broaden the clinical program for MT103 and initiate a first clinical trial for MT110. We will also advance our earlier-stage BiTE antibodies and report on results at clinical and scientific conferences. In addition, we expect to start a phase 2 clinical trial with adecatumumab (MT201) in adjuvant disease in the second half of 2008. Finally, we will continue to explore opportunities for new collaborations in 2008."

Financial Results:

Quarter Ended December 31, 2007

For the three months ended December 31, 2007, Micromet recognized revenues of $7.0 million, compared to $13.8 million for the same period in 2006. Included in 2006 revenues was the receipt of a $10.0 million milestone payment
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
2. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
3. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
4. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
5. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
6. Helix BioPharma reports Q2 2008 highlights, financial results
7. Oncothyreon reports full year and fourth quarter 2007 financial results
8. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
9. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
10. ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
11. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , 25 novembre 2014 Theravalues Corporation ... sur le marché européen au salon Hi Europe ... Amsterdam ). Curcumine la plus ... technologie amorphe (non-cristalline) à des ingrédients approuvés par ... un pigment jaune présent dans la racine de ...
(Date:11/26/2014)... 2014 /PRNewswrie/ -- Theravalues Corporation annuncia con orgoglio il ... occasione di Hi Europe 2014 (dal 2 al 4 ... tratta della curcumina con la maggiore biodisponibilità di sempre, ... ingredienti approvati dalle norme europee. La curcumina ... curcumina ( Curcuma longa ) che è stata associata ...
(Date:11/24/2014)... 24, 2014  IGI Laboratories, Inc. (NYSE MKT: IG), ... generic pharmaceutical company, today announced it has submitted an ... Food and Drug Administration (FDA), which brings the Company,s ... with eighteen submissions now pending at the FDA. ... of the Company, commented, "Our team here at IGI ...
(Date:11/24/2014)... 2014  Last week, Representatives Gus Bilirakis ... took a bold bipartisan step on behalf of ... Act. Original co-sponsors of the legislation include Representatives ... incentivize drug makers and innovators to "repurpose" major ... cancers, which opens the door to the development ...
Breaking Biology Technology:La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 3La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3IGI Laboratories, Inc. Announces ANDA Submission 2OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2
... Century Biochemicals, Inc . of Marlborough, MA ... of the 5,000 fastest-growing private companies in the country for ... Biochemicals was ranked #2626 after being ranked #575 in 2008 ... look at the most important segment of the economy – ...
... Group, LLC today announced that the Company,s Co-Presidents, Melody Carey ... on Wednesday, September 1, 2010 at The NASDAQ MarketSite in ... of providing award-winning communications counsel to the life sciences and ... Bell ceremony will begin at 3:50 p.m. ET and can ...
... (OTC Bulletin Board: GOVX ), a biotechnology company ... the results of its Annual Shareholders Meeting, held on August ... nominees for directors of the company to serve until the ... duly elected or appointed and qualified. They are: ...
Cached Biology Technology:21st Century Biochemicals Marks Its Third Consecutive Year on the Inc. 5000 2Rx Communications Group to Ring NASDAQ Closing Bell 2GeoVax Labs Inc. Announces Results of 2010 Annual Stockholders Meeting 2GeoVax Labs Inc. Announces Results of 2010 Annual Stockholders Meeting 3GeoVax Labs Inc. Announces Results of 2010 Annual Stockholders Meeting 4
(Date:11/5/2014)... Redmond has dedicated his career to understanding the ... general audience. , As deputy director and regional ... Nevada,s Desert Research Institute, Redmond has more than ... and dissemination of climate data to the general ... in San Francisco on December 15-19, 2014 the ...
(Date:11/4/2014)... Medicine announced today that it is a Grand ... Bill & Melinda Gates Foundation. Laura Goetzl, ... Sciences; and Vice Chair of Research and Academic ... pursue an innovative global health and development research ... Neurodevelopment.", Grand Challenges Explorations (GCE) funds individuals worldwide ...
(Date:11/4/2014)... – A majority of Madagascar,s 101 species of lemurs ... consequences for the rainforests they call home. A new ... lemurs can have on rainforest tree populations, which raises ... on the region,s rich biodiversity. , A large proportion ... lemurs. Lemurs in turn disperse the seeds of ...
Breaking Biology News(10 mins):Nevada climatologist to be honored at AGU Fall Meeting for lifetime of public outreach 2Temple University School of Medicine receives Grand Challenges Explorations grant 2Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3
... consortium of researchers has published the genome sequence of ... chimpanzee and human genomes. Published April 13 in a ... that the three primate species share about 93 percent ... their genes. , In its paper, the Rhesus Macaque ...
... found an unsuspected link between the immune system and high ... mice. The finding could lead to new ways to reduce ... , In the April 13, 2007, issue of ... PhD student, in the laboratory of Yang-Xin Fu, MD, PhD, ...
... associated with asbestos exposure ?have a higher survival rate when ... multicenter study finds. , Mesothelioma, a rare but aggressive form ... heart and abdomen, is associated with exposure to asbestos. There ... receiving pemetrexed and cisplatin ?along with the vitamin supplements folic ...
Cached Biology News:Analysis of rhesus monkey genome uncovers genetic differences with humans, chimps 2Analysis of rhesus monkey genome uncovers genetic differences with humans, chimps 3Link found between immune system and high plasma lipid levels 2Chemo combination improves survival in asbestos-related cancer 2Chemo combination improves survival in asbestos-related cancer 3
ABgene® supplies a 94kDa ultra-pure recombinant thermostable DNA polymerase obtained by high level expression of the Taq DNA polymerase gene in E. coli....
... is a thermostable DNA polymerase derived ... at temperatures above 70°C, it was ... PCR and remains the predominant enzyme ... an intrinsic 5'?3' structure-dependent exonuclease activity, ...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (F1676) or contact customer s...
... number is a new ... easily match Cornings product ... availability yet, please order ... number (Z71,448-8) or contact ...
Biology Products: